» Articles » PMID: 34948414

Computer-Based Drug Design of Positive Modulators of Store-Operated Calcium Channels to Prevent Synaptic Dysfunction in Alzheimer's Disease

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Dec 24
PMID 34948414
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Store-operated calcium entry (SOCE) constitutes a fine-tuning mechanism responsible for the replenishment of intracellular stores. Hippocampal SOCE is regulated by store-operated channels (SOC) organized in tripartite complex TRPC6/ORAI2/STIM2. It is suggested that in neurons, SOCE maintains intracellular homeostatic Ca2+ concentration at resting conditions and is needed to support the structure of dendritic spines. Recent evidence suggests that positive modulators of SOC are prospective drug candidates to treat Alzheimer's disease (AD) at early stages. Although STIM2 and ORAI2 are definitely involved in the regulation of nSOC amplitude and a play major role in AD pathogenesis, growing evidence suggest that it is not easy to target these proteins pharmacologically. Existing positive modulators of TRPC6 are unsuitable for drug development due to either bad pharmacokinetics or side effects. Thus, we concentrate the review on perspectives to develop specific nSOC modulators based on available 3D structures of TRPC6, ORAI2, and STIM2. We shortly describe the structural features of existing models and the methods used to prepare them. We provide commonly used steps applied for drug design based on 3D structures of target proteins that might be used to develop novel AD preventing therapy.

Citing Articles

Structural and accessibility studies highlight the differential binding of clemizole to TRPC5 and TRPC6.

Saqib U, Demaree I, Obukhov A, Baig M, Khan M, Altwaijry N J Biomol Struct Dyn. 2024; :1-14.

PMID: 38279926 PMC: 11412694. DOI: 10.1080/07391102.2024.2306198.


Bioinformatics investigation on blood-based gene expressions of Alzheimer's disease revealed ORAI2 gene biomarker susceptibility: An explainable artificial intelligence-based approach.

Sekaran K, Alsamman A, George Priya Doss C, Zayed H Metab Brain Dis. 2023; 38(4):1297-1310.

PMID: 36809524 PMC: 9942063. DOI: 10.1007/s11011-023-01171-0.


A Perspective: Challenges in Dementia Research.

Stecker M Medicina (Kaunas). 2022; 58(10).

PMID: 36295529 PMC: 9609997. DOI: 10.3390/medicina58101368.

References
1.
Neves M, Totrov M, Abagyan R . Docking and scoring with ICM: the benchmarking results and strategies for improvement. J Comput Aided Mol Des. 2012; 26(6):675-86. PMC: 3398187. DOI: 10.1007/s10822-012-9547-0. View

2.
. Strategies for 3D pharmacophore-based virtual screening. Drug Discov Today Technol. 2013; 7(4):e203-70. DOI: 10.1016/j.ddtec.2010.11.004. View

3.
Vaeth M, Yang J, Yamashita M, Zee I, Eckstein M, Knosp C . ORAI2 modulates store-operated calcium entry and T cell-mediated immunity. Nat Commun. 2017; 8:14714. PMC: 5355949. DOI: 10.1038/ncomms14714. View

4.
Pei J, Wang Q, Liu Z, Li Q, Yang K, Lai L . PSI-DOCK: towards highly efficient and accurate flexible ligand docking. Proteins. 2006; 62(4):934-46. DOI: 10.1002/prot.20790. View

5.
Popugaeva E, Chernyuk D, Zhang H, Postnikova T, Pats K, Fedorova E . Derivatives of Piperazines as Potential Therapeutic Agents for Alzheimer's Disease. Mol Pharmacol. 2019; 95(4):337-348. PMC: 6402417. DOI: 10.1124/mol.118.114348. View